An effect of hormone replacement therapy on cataract and glaucoma in postmenopausal women.

An effect of hormone replacement therapy on cataract and glaucoma in postmenopausal women: A parallel group, case-control study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN72439325

Enrollment

264

Registered

2014-06-18

Start date

2012-06-01

Completion date

Unknown

Last updated

2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract and glaucoma Eye Diseases

Interventions

Hormone replacement therapy

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Eligible patients included postmenopausal women at least 5 years of postmenopausal period, who either: 1. Never used HRT (Group 1: 128 patients) after menopause 2. Continuously used HRT (Group 2: 136 patients) for more 5 years from menopause

Exclusion criteria

Exclusion criteria: 1. A history of any ocular injury or disorder 2. An infection, inflammation, surgery within the prior 6 months 3. Any uncontrolled systemic disease, or significant illness

Design outcomes

Primary

Measure	Time frame
Cortical, nuclear, and posterior subcapsular density, pentacam nucleus staging (PNS), pentacam densitometry of zone (PDZ) measured by pentacam.	—

Secondary

Measure	Time frame
Antioxidant and inflammatory cytokines activities in serum.	—

Countries

Korea, South

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026